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1.0 Abstract: 
Oxidation-reduction potential (ORP) measurement has demonstrated oxidative 
stress in patients with severe illness/injury. A new ORP diagnostic platform using 
disposable sensors (Supplemental Figure 1) has been validated by comparison to mass 
spectrometry, but the response of ORP to experimental positive and negative control 
conditions has not been determined.  Furthermore, optimal methods of sample handling 
for ORP measurement have not been studied.  We sought to optimize ORP measurement 
in human plasma, under controlled conditions. We hypothesized that freeze-thawing of 
the sample, storage of the sample for up to one month, and the method of sample 
anticoagulation would influence ORP levels.  Furthermore, we hypothesized that ORP 
can detect incremental experimental changes that either increase or decrease redox 
state.  Finally, we hypothesized that trauma injuries cause increased levels of reactive 
oxygen species (ROS) in the circulating bloodstream, and therefore would reflect higher 
ORP signals in plasma measurements in both human and mouse subjects.   
We enrolled healthy human volunteers in a prospective observational study and 
measured ORP in plasma prepared with heparin or citrate anticoagulants directly after 
blood draw and up to 28 days later.  Additionally, we evaluated the platform’s ability to 
detect an exogenous increase and decrease in ORP by performing both positive and 
negative control titrations using six different concentrations of hydrogen peroxide (H2O2) 
and two different concentrations of ascorbic acid respectively.  Lastly, we compared 
human trauma plasma samples in an uncontrolled emergency room setting with healthy 
human plasma and then mimicked this experiment in a more controlled mouse model 
experiment.  We found that fresh plasma better retains the ORP signal as compared to 
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freeze-thaw samples measured on subsequent days.  We also found that the platform 
can detect exogenous, concentration-dependent oxidations with H2O2 and reductions with 
ascorbic acid.  Furthermore, plasma prepared with heparin is more sensitive than using 
citrate anticoagulant when measuring ORP.  Also, human trauma patients’ plasma (of 
varying degrees of trauma) samples were characterized by significantly higher ORP 
signals than healthy controls when measured in heparin anticoagulant, whereas mouse 
ORP signals did not change following a controlled, moderate traumatic brain injury.  
These data indicate that the diagnostic platform is capable of detecting exogenous 
increases and decreases in ORP signal from plasma samples with validity and is sensitive 
to different concentrations of positive and negative controls.  We also show that plasma 
should be collected and centrifuged in heparin anticoagulant tubes and can be analyzed 
fresh or frozen for optimal results. 
 
2.0 Introduction: 
Reactive oxygen species (ROS) are byproducts of cellular metabolism, primarily 
via oxidative phosphorylation, as a result of mitochondrial respiration. ROS are essential 
signaling molecules under normal physiological conditions that contribute to a variety of 
biochemical pathways including but not limited to cell differentiation, gene transcription, 
and cell cycle progression1,2.  However, ROS cause toxic effects as they accumulate.  In 
biological systems, antioxidants produced internally or acquired by diet detoxify these 
reactive intermediates to limit damage to cells (Supplemental Figure 2).  Either an 
increase in ROS generation or an impairment of antioxidant capabilities causes an 
imbalance known as oxidative stress.  
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Recent studies suggest that oxidative stress arises and/or is associated with 
different disease states including but not limited to trauma, diabetes, and severe infection 
(sepsis)3,4,5.  Oxidative stress is a common mechanism/characteristic of disease so 
measuring it could offer insight into the pathophysiological mechanism, severity of 
disease, and potential medical therapies. For example, making a measurement of ROS 
could aid to the triage process in emergency departments and lead to more informed 
triage decisions6.  Furthermore, with additional research, it is possible that oxidative stress 
can predict disease progression and be used for monitoring the pathophysiology of 
associated conditions6.  Measuring oxidative stress may also prove valuable in the 
development of antioxidant therapy applications.  Generally, antioxidants are perceived 
as healthy compounds that exhibit preventative properties for a variety of 
neurodegenerative diseases, but little progress has been made with the medicalizing of 
them7,8,10. 
Oxidative stress can be quantified as the difference between oxidants and 
reductants (antioxidants) known as the oxidation-reduction potential (ORP)9. ORP, 
measured as the electrical signal produced by oxidation of an electrode under 
standardized conditions, provides a rapid, composite measurement of oxidative stress 
without determining contributions of individual molecules.  For clinical use, this aggregate 
measure of both oxidants and reductants, may provide more utility than other specific 
measures of oxidants alone. A novel platform has the ability to rapidly (in as little as 4 
minutes) and easily (simple experimental procedure) determine ORP levels in biological 
samples such as plasma.  Despite its potential application, we are not aware of any 
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studies that have optimized the best way for sample collection and storage conditions for 
reliable ORP measurements.   
Previous validation experiments compared comprehensive plasma ORP 
measurements from this platform to mass spectrometry measurements to confirm that 
specific proteins were oxidized, but no prior experiments have titrated different levels of 
exogenous oxidizing agents or reducing agents to establish the performance 
characteristics of the diagnostic platform under controlled conditions10,11.  Understanding 
the limits of the diagnostic platform to detect incremental changes in plasma redox states 
is necessary for optimization of a protocol for sample handling and collection.  These 
experiments also provided data that suggested trauma injuries in humans cause 
significant increase in ORP signals compared to healthy human counterparts, yet to our 
knowledge, there have been no experiments that measure ORP signal through time in a 
controlled setting1,11.  By tracking ROS through time after trauma in a controlled mouse 
model experiment, we could shed light on the pattern of ROS generation in trauma 
pathophysiology.  We sought to optimize ORP measurements in human plasma, under 
controlled conditions. We hypothesize that freeze-thawing of the sample, storage of the 
sample for up to one month, and the type of anticoagulant used to collect whole blood 
would influence ORP levels.  Furthermore, we hypothesized that ORP can detect 
incremental experimental changes that either increase or decrease redox state.  Finally, 
we hypothesized that trauma injuries cause increased levels of ROS in the circulating 
bloodstream and therefore would reflect higher ORP signals in plasma measurements in 
both human and mouse subjects. 
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3.0 Methodology: 
3.1 Subjects and Sample Collection:  
3.11 Human Subjects and Sample Collection 
This study received approval from the Institutional Review Board. Healthy human 
volunteers were recruited for this study for control plasma samples.  Trauma 
patients were also recruited for this study out of the University of Vermont Medical 
Center Emergency Department for trauma plasma samples.  Trauma injury was 
determined by emergency department staff and assigned an Injury Severity Score 
(ISS) (Supplemental Figure 3).  Trauma injuries ranged from mild to severe. Whole 
blood samples were collected from healthy/trauma volunteers through a single 
intravenous blood draw.  Whole blood was then transferred into both heparin and 
sodium citrate (3.2%) anticoagulant tubes and immediately centrifuged at 2000 
rpm4 C for 10 min.  After centrifugation, plasma samples were either aliquoted and 
stored at -80°C for future use or immediately prepared and analyzed through use 
of the diagnostic platform. 
3.12 Mouse Subjects and Sample Collection 
C57 Mice (control mice) were used for the duration of the mouse experiments.  
Blood collection in mice was performed using the cardiac puncture method in 
which whole blood collection occurred directly from the left ventricle of the heart 
through use of a syringe.  All mice were euthanized prior to whole blood collection.  
Whole blood samples were placed in heparin anticoagulant tubes Heparin tubes 
were centrifuged (10 min, 2000 rpm, 4 °C).  After centrifugation, plasma samples 
were analyzed through use of the diagnostic platform. 
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3.2 ORP Measurements: 
Measurements were taken using the RedoxSYSTM platform from Aytu BioSciences9.  
Prior to ORP measurement, all platforms were measured for calibration (Supplemental 
Figure 4).  Sensor chip side A was inserted into the device to ensure the device was within 
specification (100 mV ± 1) and then side B was inserted to further ensure the device was 
working within specification (300 mV ± 4.2).  Following calibration check, plasma samples 
(30 µL) were pipetted onto the exposed filter paper reservoir of the disposable test 
sensors and then inserted in the platform for OPR measurements.  Once applied to the 
reservoir, the sample flowed to the platinum electrode surface and current was measured 
in mV.  The final reading was the aggregate measurement of the balance of oxidants and 
antioxidants in the plasma sample.   
3.3 Experimental Design: 
3.31 Control Time Course: 
Following centrifugation, ORP signal was measured from human plasma collected 
in the sodium citrate (3.2%) tube and then in the heparin tube in duplicate to 
establish a time zero (fresh) measurement.  The rest of the plasma was aliquoted 
into cryovials (100 µL aliquots) and stored at -80°C for later use.  One aliquot of 
citrate derived plasma and one aliquot of heparin derived plasma were removed 
from the -80°C condition and placed at room temperature until they had completely 
thawed.  The samples were analyzed in duplicate at different time points as 
follows: 2, 4, 6, 21, and 21 days after time zero measurement to determine stability 
of sample through time and through freeze-thaw event.   
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3.32 Elevated Time Course: 
Following centrifugation, plasma samples were aliquoted into cryovials (100µL 
aliquots) as described above.  Aliquots were then oxidized by adding 1% H2O2 
(known as a potent oxidant).  ORP signal was then measured from a citrate tube 
aliquot and a heparin tube aliquot in duplicate to establish a time zero (fresh) 
measurement.  The rest of the aliquots were stored at -80°C for later use.  As in 
the control time course, samples were again measured in duplicate at time points 
2, 4, 6, 21, and 28 days after time zero measurement to determine stability and 
retention of an exogenously elevated ORP signal through time and through freeze-
thaw event.   
3.33 Positive Control Titration: 
Following centrifugation, ORP signal was measured from both citrate and heparin 
plasma samples in duplicate.  The remaining plasma was then titrated by adding 
increasing concentrations of H₂O₂, specifically 0.03, 0.1, 0.3, 1, 3, and 10% of 
H₂O₂ solutions.  Each of these samples were then tested in duplicate to determine 
the platform’s ability to detect exogenous elevations in oxidative stress as 
compared to the control samples.   
3.34 Negative Control Titration: 
Following centrifugation, ORP signal was tested from both citrate and heparin 
plasma samples in duplicate.  The remaining plasma was then titrated into 10 and 
50 mM ascorbic acid solutions.  Both of these samples were then tested in 
duplicate to determine whether control plasma could be reduced below the basal 
reading as determined by the platform’s ability to detect exogenous reductions in 
David A. Polson: Honors Thesis 
 
11 
 
oxidative stress of different concentrations as compared to the control sample.  In 
addition to reducing basal plasma, another negative control titration was performed 
by first elevating (oxidizing) the plasma by adding 0.1% H₂O₂ prior to the addition 
of ascorbic acid (10 mM and 50 mM) in order to mimic an elevated signal of a 
clinical condition.   
3.35 Human Healthy Control vs. Trauma Plasma 
Following centrifugation, plasma ORP was measured from healthy, control 
volunteers   in citrate and then in the heparin tube in duplicates.  These data were 
then compared to ORP measurements obtained from consented trauma patients.  
Trauma patient plasma was also measured from citrate tube and then heparin tube 
in duplicates. 
3.36 Mouse Healthy Control vs. Trauma Plasma Time Course 
All healthy control mouse blood was collected via cardiac puncture and analyzed 
in duplicate using the diagnostic platform immediately following centrifugation.  
Trauma mice were induced a traumatic brain injury (TBI) via fluid percussion25,26.  
Following fluid percussion, split into 2 groups; 4hr and 12hr groups.  4hr and 12hr 
mice were euthanized at their respective time points and blood was collected via 
cardiac puncture.  Following centrifugation, plasma was immediate analyzed in 
duplicate using the diagnostic platform. 
3.4 Statistical analysis: 
Average ORP values are reported as mean ± standard error mean (s.e.m.) N represents 
number of replicates per experiment. All data was analyzed using two-way ANOVA 
statistical analyses with the exception of healthy human control vs. trauma patient data 
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which was analyzed via unpaired T-test.  All analyses were conducted through use of 
GraphPad Prism. 
 
4.0 Results: 
4.1 Effects of Freeze-Thawing Human Plasma and Sample Storage: 
Freeze-thawing control human plasma samples led to a decrease in ORP as 
determined by the novel diagnostic platform (Fig. 1A; Two-way ANOVA, P < 0.05, 
N=5).  Freeze-thawing exogenously elevated plasma samples also led to a 
decrease in ORP (Fig. 1, B; Two-way ANOVA, P < 0.05, N=5).   
4.2 Effects of Anticoagulant on ORP Values: 
All control plasma samples measured in heparin anticoagulant showed a marked 
decrease in ORP as compared to citrate anticoagulant counterparts (Fig. 1A; Two-
way ANOVA, P < 0.05, N=5).  In exogenously elevated plasma however, the type 
of anticoagulant had no effect on the measurement (Fig. 1, B; Two-way ANOVA, 
ns, N=5). 
4.3 Positive Control Titration on ORP Measurement in Human Plasma: 
The addition of exogenous H2O2 (0.1%) to control human plasma to create different 
concentrations of H2O2-plasma solutions led to increased ORP signals as 
determined by the novel diagnostic platform (Fig 2; Two-way ANOVA,  P < 0.05, 
N=5).  However, the type of anticoagulant had no effect on different concentrations 
of exogenously elevated plasma and resulted in consistent ORP measurements 
(Fig 2; Two-way ANOVA, ns, N=5). 
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4.4 Negative Control Titration on ORP Measurement in Human Plasma: 
The addition of exogenous ascorbic acid at two different concentrations (10 and 
50 mM) to control human plasma significantly decreased ORP signals as 
determined by the novel diagnostic platform (Fig. 3A; Two-way ANOVA, P < 0.05, 
N=5). Control plasma measured in heparin anticoagulant also showed a decrease 
in ORP vs. citrate plasma counterparts when ascorbic acid was applied (Fig. 3, A; 
Two-way ANOVA, P < 0.05, N=5).  The addition of exogenous ascorbic acid to 
plasma following the exogenous elevation of plasma to 0.1% H2O2 also led to a 
decrease in ORP in comparison to the basal 0.1% H2O2 measurement (Fig. 3B; 
Two-way ANOVA, P < 0.05, N=5).  We found no difference in ORP values between 
elevated plasma prepared in heparin vs. citrate anticoagulant (Fig. 3B; Two-way 
ANOVA, ns, N=5). 
 
4.5 Effects of Trauma on ORP Values 
Trauma injuries in humans of varying degrees led to a significant increase in 
plasma ORP signal compared to healthy human control plasma ORP readings 
when heparin anticoagulant was used (Fig. 4; Unpaired T-test, P < 0.05, N=5 
healthy control, N=10 trauma).  However, this increase as a result of trauma did 
not present itself with plasma measured in citrate anticoagulant (Fig. 4; Unpaired 
T-test, ns, N=5 healthy control, N=7 trauma).  With regard to mice, trauma injury 
had no effect on ORP signal (Fig. 5; Two-way ANOVA, ns, N=5 healthy control, 
N=4 TBI 4hr, N=3 TBI 12hr). 
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5.0 Figures: 
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Figure 1. Effect of freeze-thawing human plasma in both citrate and heparin anticoagulant and the 
stability of human plasma in storage at -80°C on  A, control human plasma (Two-way ANOVA; 
Anticoagulant P < 0.05, Time P < 0.05). and B, oxidized human plasma (1% H₂O₂) up to 28 days (Two-
way ANOVA; Anticoagulant ns, Time P < 0.05). 
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Figure 2. Effect of the addition of known oxidant H₂O₂ to human plasma at incremental 
concentrations in both citrate and heparin anticoagulants (Two-way ANOVA; Anticoagulant ns, H₂O₂ 
vs. ORP P < 0.05).  The inset shows data from 0% – 0.3% H₂O₂ concentrations. 
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Figure 3. Effect of the addition of known reductant ascorbic acid to human plasma at two 
concentrations (10mM and 50mM) in both citrate and heparin anticoagulants on A, control human 
plasma (Two-way ANOVA; Anticoagulant P < 0.05 ), ascorbic acid vs. ORP P < 0.05 ) and B, 
oxidized human plasma (0.1% H₂O₂)  (Two-way ANOVA; Anticoagulant ns, ascorbic acid vs. ORP 
P < 0.05 ). 
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Figure 4. Effect of traumatic injury to human plasma ORP signal in citrate and heparin anticoagulant 
(Unpaired T-test; Control vs. Trauma citrate ns, Control vs. Trauma heparin P < 0.05 (*)).  Trauma 
ORP measurements were taken upon arrival to emergency department (time zero).  Trauma injuries 
varied from mild to severe and trauma patients varied in age and sex.  All readings were pooled. 
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6.0 Discussion: 
Measurement of redox state has been around for quite some time.  Originally, the 
standard potential of a redox system Eo (from the Nernst-Peters equation) was measured 
by electrodes similar to those of the novel diagnostic platform.  These electrodes however 
measured redox potential by implantation into subcutaneous tissue.  While electrodes 
could also be placed in biological samples (similar to the diagnostic platform), issues 
arose in the reliability and reproducibility of the older methods that measured the entire 
redox state of the system not to mention that a much larger volume of a biological sample 
was needed to fully immerse electrodes.  Other, more successful older methods were 
specific to the redox potential estimations by measuring individual molecules or groups 
of molecules from a sample as oppose to the entire sample as a whole12.  Among this 
was a fluorometric device that measured pyridine nucleotides and cytochromes13,14.  The 
issue with this method arose from the in vivo/in situ preparation of the sample.  The 
method required that the sample be exposed so the fluorometric device’s primary use 
was to measure redox in animal models or preserved organ tissues12,14. 
The novel diagnostic platform measures redox state in biological samples ex vivo.  
It measures the entirety of the sample without focusing on individual types of molecules 
like the fluorometric method and several other older methods.  Similar to the original 
electrode method, this platform has been validated with regard to accuracy through 
comparison to mass spectrometry in which specific protein show increased oxidation 
states in samples that elicit a greater ORP value as compared to control ORP 
samples10,11.  Furthermore, the platform’s use of disposable test sensors results in a 
reproducible and reliable method of ORP measurement as compared to previous 
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methods6.  The platform also provides a much quicker and cheaper alternative to current 
analyses of ORP including mass spectrometry15.   
This is the first study conducted to optimize a protocol for this novel point-of-care 
platform through from sample collection through measurement.  Furthermore, the 
platform had not yet been validated through the addition of exogenous oxidants and 
reductants to control human plasma to measure changes in ORP level.  We sought to 
optimize ORP measurement in human plasma, under controlled conditions. We 
hypothesized that freeze-thawing of the sample, storage of the sample for up to one 
month, and the method of sample anticoagulation would influence ORP levels.  
Furthermore, we hypothesized that the platform can detect incremental experimental 
changes that either increase or decrease redox state and therefore lead to 
misinterpretations of experimental findings.  Our findings suggest that sample integrity 
exists through storage at -80°C conditions, however freeze-thaw cycles result in a 
significant decrease in the signal of both control and exogenously elevated plasma 
samples compared to fresh plasma counterparts.  Also, the type of anticoagulant used 
for whole blood processing directly effects basal plasma ORP readings.  With regard to 
our validation experiments, we found that the device accurately detects concentration 
dependent additions of both exogenous oxidants and reductants to human plasma 
samples. 
 
6.1 Effect of Freeze-Thawing and Storage of Sample on ORP Values: 
 We conducted this set of experiments to test whether plasma samples’ redox state 
remained constant through freeze-thaw cycles and whether ORP signal remains stable 
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through time as a result of storage.  We saw this as an essential experiment; the Freeman 
laboratory has collected and stored many frozen plasma samples from both control 
subjects and trauma patients but the validity of retrospective analyses would be 
compromised if freeze-thaw or storage affect ORP measurement.  Figure 1A suggests 
that there is a significant deterioration (decrease) in the ORP signal (5-10 mV drop) as a 
result of freeze-thaw cycles in plasma samples collected in both citrate and heparin tubes 
as compared to fresh plasma ORP measurements.  This drop in ORP signal remained 
constant through storage at -80°C conditions of up to one month in time (Figure 1A).  This 
suggests that, though there is a drop in signal due to freeze-thawing, the samples remain 
stable when storage at -80°C.  We also measured the stability of the ORP signal in 
samples elevated with exogenous H2O2 (1%) to mimic the ORP signal obtained in a 
severe disease state such a sepsis or trauma (Figure 1B).  Our results were identical to 
the control plasma time course where a significant drop in ORP occurred following freeze-
thawing.  This drop also remained constant through time.  These data suggest that for 
optimal and most accurate results, fresh ORP measurements are preferred; we have 
concluded that frozen samples are incomparable to samples measured fresh. 
 A previous study measured the effect of storage time on sample integrity and 
concluded that samples stored at -80°C remain unchanged up to 6 months after initial 
blood draw6.  This result confirms our findings that plasma samples remain stable through 
proper storage.  However, this study did not compare fresh plasma ORP readings with 
freeze-thawed plasma ORP readings.  Since ORP signal significantly drops following a 
freeze-thaw cycle, we conclude that fresh ORP readings and freeze-thaw ORP readings 
are incomparable with regard to plasma. 
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6.2 Effect of the Anticoagulant on ORP Values: 
In this study, we evaluated the influence of two different anticoagulants (heparin 
and sodium citrate) on ORP values measured in either citrated or heparinized human 
plasma.  The use of an anticoagulant proves necessary due to the device limitation being 
unable to process whole blood samples; they coagulate in the disposable test sensor 
before reaching the platinum electrodes making it impossible to provide a reliable ORP 
measurement.  Under normal circumstances, coagulation occurs when thrombin converts 
fibrinogen to fibrin.  Once initiated, clot formation is driven by the activation of plasma 
glycoproteins that exhibit serine protease activity.  These zymogens drive the reaction to 
completion and among them are thrombin and coagulation factors X and IX16.  Heparin 
effectively acts as an anticoagulant because of its ability to increase the activity of the 
inhibitory antithrombin enzyme.  Upregulating of antithrombin activity inhibits factors X 
and IX activity to contribute to coagulation17,18. 
  On the other hand, sodium citrate sequesters calcium ions in vitro19.  Calcium is a 
necessary second messenger in blood clot formation mediating the activation of 
zymogens into their active enzyme states including factor IX which in turn activates factor 
X16.  In the presence of sodium citrate, calcium required for blood clotting is neutralized. 
The activation of factors IX and X ceases as the calcium necessary for the reaction has 
been depleted leading to the overall inhibition of the coagulation pathway. 
 We found that plasma derived from heparin anticoagulant tubes had significantly 
lower baseline ORP measurements than plasma derived from citrate anticoagulant tubes.  
Figure 1A illustrates this difference and suggests that the difference in ORP signal 
between anticoagulant type remains regardless of freeze-thawing.  The chelation of 
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calcium ions achieved by sodium citrate may lead to a significant increase in redox state 
while the potentiation of antithrombin via heparin does not have this effect.  One study 
found that the administration of heparin during hemodialysis led to a significant decrease 
in the release of superoxide free radicals which suggests an alternate explanation for why 
baseline heparin ORP readings were lower than citrate20. 
 Interestingly, following the addition of the oxidant H2O2, ORP measurements 
between heparin and citrate plasma reach a steady plateau (Figure 2).  This suggests 
that plasma reaches a maximum oxidizable state that is consistent between heparin and 
citrate.  This consistency between anticoagulants remains upon the reduction through 
ascorbic acid of highly elevated samples (Figure 3, B).  But the difference in ORP between 
heparin vs. citrate exists after the addition of an exogenous reductant (in our case 
ascorbic acid) in basal samples without previous elevation.  Figure 3A shows this pattern 
as heparin ORP signals remain significantly lower than citrate measurements even after 
the addition of ascorbic acid (10 mM and 50 mM).  In other words, the difference in ORP 
is sustained by exogenous decreases in redox state yet abolished by exogenous 
increases in redox state.  This suggests that as redox state increases, ORP 
measurements in heparinized plasma and ORP measurements in citrated plasma will 
ultimately converge whereas when redox state decreases, ORP values will remain 
definably different between the two types of anticoagulants. 
 
6.3 Positive and Negative Control Validation of Platform: 
 No studies have tested the effects of exogenous oxidants and reductants on ORP 
signal when added to plasma samples.  We saw this as an important set of data to deduce 
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the sensitivity of the platform and to ensure that the platform was actually sensing 
changes in redox state.  First, we conducted a positive control titration using increasing 
concentrations of H2O2, a known oxidant.  Our data suggest that the device can detect 
concentration dependent increases in ORP as a result of the addition of H2O2 (Figure 2).  
ORP measurements maxed out at around 230 mV and began to plateau by a 
concentration of 1% H2O2.  Next, ascorbic acid was used on control plasma to determine 
the lower bounds of the device with regard to plasma.  Figure 3A illustrates a significant 
reduction in ORP signal of control plasma after the addition of two different concentrations 
of ascorbic acid (10 mM and 50 mM), suggesting that plasma obtained from healthy 
(control) individuals also contain circulating oxidized proteins that can be further reduced.  
Furthermore, we confirmed that the platform could detect changes in ORP by first 
oxidizing control plasma with H2O2 (0.1%) and then adding ascorbic acid to decrease the 
signal as shown in Figure 3B.  The data present a much more drastic decrease in signal 
in response to the ascorbic acid treatment used in comparison to the decrease seen in 
Figure 3A, suggesting that the changes in ORP are a direct result of changes in redox 
states.  As more proteins become oxidized through H2O2 treatment leading to an overall 
greater potential for reduction after ascorbic acid treatment. 
 One similar study measured the effects of ascorbic acid on ORP signal of a 
phosphate-buffered saline (PBS) solution as a negative control experiment using the 
same platform.  They produced similar results as they reported that the platform was able 
to detect incremental changes in ascorbic acid that resulted in the overall decrease in 
redox state1.  Our data further validate the ability of the device to detect decreases in 
ORP signal when plasma samples are exogenously treated with an antioxidant. 
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6.4 Effects of Trauma Injuries on ORP Values: 
 Several studies have tested the effect of trauma on plasma ORP in humans with 
this novel platform.  In all cases, trauma has led to a significant increase in plasma ORP 
vs healthy control human subjects1,10,11.  In each of these studies, heparin was the 
anticoagulant used for sample preparation.  We decided to verify these results and also 
to evaluate the effects of citrate on ORP in control and trauma plasma samples.  Our data 
confirm the previous studies findings in heparin, however we didn’t see any change in 
ORP signal when using the citrate anticoagulant between trauma and healthy control 
volunteers.  We believe that the lower basal readings in heparin allow for the detection of 
increases in ORP characterized by trauma injuries while citrate anticoagulant is not 
sensitive enough at these lower changes in ORP.  If we recall the positive titration data 
(Figure 2), we did not see a difference between heparin and citrate anticoagulant.  This 
is because at maximal H₂O₂ concentrations, plasma ORP is maximized and a steady 
plateau is reached consistent between anticoagulants, denying statistical significance.  
Trauma injuries do not produce ORP readings nearly as high as the plateau.  By our 
results, trauma ORP mimics a 0.03% H₂O₂ plasma solution.  At these low concentrations, 
a much greater change in ORP signal exists in heparin measurements than citrate which 
could account for why trauma goes undetected when using citrate anticoagulant.   
 Inclusion criteria for trauma patients consisted of any patient admitted to University 
of Vermont Medical Center Emergency Department requiring immediate medical 
attention as determined by the medical staff.  Patients age and injury severity score (ISS) 
(when applicable) are listed in supplemental figure 5.  ISS is a scoring system that adds 
the squares of the three highest abbreviated injury scale (AID) values (range 1-5 to score 
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different parts of the body) and is a statistic used almost exclusively for research 
methodology.  It is a strong predictor of trauma severity and mortality21.  Included in this 
study were patients who suffered a mild to severe trauma of any kind.  Previous studies 
stratified their results into different subsets of trauma.  One such study separated multi-
trauma patients by ISS where all patients who scored less than 16 were in a different from 
those who scored 16 or greater10.  As compared to control readings, both trauma groups 
showed significant increases in plasma ORP and the ≥ 16 ISS trauma group was further 
elevated as compared to the < 16 ISS group.  This suggests that, greater ORP values 
are associated with more severe trauma injuries and like the positive control titration, the 
platform can detect these incremental changes.  While we did not stratify our data in this 
study, our data confirms previous results.  
 While trauma injuries take on many shapes, one particular study measured TBI 
specific trauma with regard to ORP in human plasma.  The results were similar to other 
literature where trauma led to significant increase in plasma ORP signal1.  The platform’s 
ability to measure the difference between TBI and healthy status suggests application 
outside the hospital.  TBI is a common injury acquired in contact sporting events including 
football, hockey, boxing, etc.  Many patients come to the emergency department without 
actually suffering TBIs while many patients suffering TBI do not end up making it to the 
emergency department due to delayed or nonexistent symptoms.  This platform offers a 
quick, convenient means to measure the severity of TBI before reaching the hospital 
which may help correct improper procedure following a head injury.  Current biomarkers 
of TBI include a variety of cerebrospinal fluid and/or blood indicators22,23,24.  One more 
popular biomarker is the tau protein, a central nervous system protein that helps stabilize 
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microtubules.  Tau increases in blood as a result of TBI23,24.  While this biomarker 
accurately indicates TBI, ORP measurement provides a much quicker, cheaper, and 
simpler means to the same end. 
 Stemming from the human TBI results reported by previous studies along with our 
own findings, we decided to undertake a controlled, mouse model time course experiment 
exploring the pattern of ORP at different time points after TBI.  TBI was induced via fluid 
percussion which allows for the most consistent and controlled administration of TBI.  A 
pendulum swings from 10 degrees (maximum injury with approximately 2:3 survival rate 
in mice) and strikes a piston of a fluid reservoir, sending a pressure pulse to the dura of 
the mouse (Supplemental Figure 6).  This method does not induce skull fracture which 
attributes to its consistency25,26.   Following blood draw, the brains of the mice that 
received TBI treatment were examined to confirm TBI.   Surprisingly, we found that ORP 
signal did not increase in TBI mice at 4 or 12 hours after trauma as compared to healthy 
control mice which contradicts previous studies and our results in human trauma 
patients1,11.  It is possible that fluid percussion induced mice experience TBI without 
severe neurological impairment or that mice have alternate redox systems than humans, 
both of which could explain this anomaly.  Another explanation is the low N in our 
experiment.  With increased measurements, we may potentially see a difference, though 
so far, that data suggests that the trauma pathophysiology of mice is different and 
therefore incomparable to the pathophysiology of humans in relation to ORP signals 
(Supplemental Figure 7). 
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6.5 Conclusion: 
 We were able to establish a protocol for the diagnostic platform to optimize ORP 
measurements.  Freeze-thawing human plasma had a significant effect on ORP signal 
resulting in overall lower ORP as compared to fresh plasma readings; therefore, we 
suggest that plasma always be measured either fresh, frozen for the duration of an 
experiment for comparable results.  Furthermore, we conclude that the proper storage of 
human plasma (-80°C) has no foreseeable effect on ORP signal, and one may 
retrospectively analyze plasma samples that have been stored for accurate results 
(assuming there is no cross comparison between fresh and freeze-thaw samples).  Also, 
we suggest the usage of heparin anticoagulant over citrate anticoagulant when measuring 
the effects of different disease states on ORP due to heparin’s greater sensitivity to 
oxidizing effects at lower ORP levels.  The use of citrate may result in nonsignificant 
results between disease state and healthy control. 
 We were able to validate the platform with regard to exogenous positive (oxidation) 
and negative (reduction) controls.  We conclude that the device is performing within 
specification due to its ability to distinguish between exogenous oxidants and 
antioxidants.  Furthermore, we found that it is sensitive to different concentrations of each. 
 Based on these data, we believe that this novel platform has a vast range of 
potential applications.  With its ability to detect increases in ORP in patients suffering from 
trauma, it has clinical significance.  Especially since it can measure ORP in as little as 4 
minutes when alternate methods take much longer.  Much literature associates increases 
in ROS as a characteristic of a variety of different disease/conditions.  We have shown 
that trauma injuries reflect an increase in circulating ROS, and with the exploration of 
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other conditions, it is possible that the device will aid in other diagnoses.  It may become 
an invaluable step during triage and disease progression monitoring.  We suggest that 
future studies explore the effects of alternate disease states on ORP as determined by 
the diagnostic platform. 
 
7.0 Supplemental Figures: 
7.1 The Novel Diagnostic Platform 
 
 
 
 
 
 
 
 
 
 
 
 
A.The diagnostic platform is a battery-powered device consisting of a heads up display 
and a reader slot for the disposable test strips.  B.  A disposable test strip is inserted into 
the reader slot of the device where a human biological substance is pipetted into the 
reservoir of the test strip.  C.  Once the sample crosses the bridge and reaches the 
electrodes, the device measures the current between the reference and working 
electrodes.  Current is measured every 0.5 seconds resulting in a raw data trace.  The 
final reading is the average of the last 10 seconds of readings9. 
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7.2 Endogenous Reactive Oxygen Species and Antioxidants 
 
 
 
 
This table depicts the common endogenous ROS and 
antioxidants under normal physiological conditions.  The 
flowchart depicts the ROS pathway from oxygen singlet to 
water (mediated by antioxidants)9. 
 
 
 
 
 
7.3 Description of Injury Severity Score 
 
 
 
 
 
 
 
Sample injury severity score for a multi trauma patient with a head/neck injury and an 
extremity injury.  Of the regions listed, an injury description is provided (or marked “no 
injury” if there is no injury for said region).  Next, the injury is scored on the abbreviated 
injury scale (AIS).  This is done by the attending physician and ranges from 1-5, 1 being 
mild and 5 being most severe.  Finally, the highest 3 AIS scores are squared and reported 
in the final column where they are summed for the overall (ISS).  An ISS greater than or 
equal to 16 is considered severe (life threatening)21. 
 
 
ROS Antioxidant 
Oxygen (Singlet) Glutathione 
Superoxide Catalase 
Hydrogen Peroxide Superoxide Dismutase 
(SOD) Hydroxyl Radical 
Region Injury description 
Abbreviated Injury Scale 
(AIS) 
Square of Three 
Major Injuries 
Head/Neck Traumatic Brain Injury  3   9 
Face No Injury   0    
Thorax No Injury   0    
Abdomen No Injury   0    
Extremities  Fractured Humerus 2 4  
Skin No Injury   0    
  Total (ISS):  13 
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7.4 Calibration Check Data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Machines retained calibration through time as determined by calibration chip side “A” 
and side “B.”  Upper and lower Y-axis limits represent the acceptable boundaries of 
calibration values. 
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7.5 Trauma and Control Volunteer Demographics 
 
 
 
 
 
 
Citrate trauma subjects ranged from 27-80 years in age and had ISS scores ranging from 
9-13.  N/A denotes patients who were not assigned an ISS score due to early hospital 
discharge and were classified as mild trauma patients.  Heparin trauma subjects ranged 
from 18-53 years of age and had ISS scores ranging from 1-18.  Control subjects included 
12 individuals ranging from 20-35 years of age.  All three groups consisted of mixed male 
and female volunteers. 
 
 
7.6 Fluid Percussion Diagram 
 
  
 
 
 
 
 
 
 
 
 Diagram of fluid percussion and its components26. 
 
 
 
Citrate Trauma Heparin Trauma Control 
Age ISS Age ISS Age Range: 
80 13 53 9  20-35 
66 9 27 13  
34 N/A 32 1  
56 9 18 18  
27 N/A 50 17  
Pendulum 
Piston 
Fluid Reservoir 
Mouse 
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7.7 Mouse TBI Time Course Data 
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The data is inconclusive due to small N.  However, as the data stands, there is no 
significance between Control, 4hr TBI, and 12hr TBI groups using a one-way 
ANOVA test (24 hr TBI group needs higher N for statistical analyses). 
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